Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience

Background: Type 2 inflammation plays a pivotal role in various allergic and inflammatory diseases, including chronic rhinosinusitis (CRS), asthma, atopic dermatitis (AD), and eosinophilic esophagitis (EE). Dupilumab is one of the emerging therapeutic targets that modulates the key mediators and cellular players involved in type 2 inflammation, aiming to improve the immune response and the quality of life (QoL) of the patient. Objective: Here we describe the experience made on 792 patients enrolled by several specialists of a multidisciplinary team working on inflammatory Type 2 diseases. Design: retrospective study. Methods: Patients were treated with dupilumab according to the prescribed indications and were evaluated by several exams, tests and questionnaires at baseline (T0) and after 12 (T1), 18 (T2) and 24 (T3) months. Results: Overall, dupilumab exerts beneficial effects as demonstrated both by patients-reported outcomes and by objective assessments. Compared to baseline, all examined efficacy indicators showed an improvement after 12 months, with positive effects sustained through the two years of observation. Our results align with several previous trials. Conclusion: Understanding the interconnection between different type 2 inflammatory diseases provides insight into potential avenues for precision medicine approaches and targeted therapies.